ARTICA Therapeutics and its seasoned team started operatons in 2020 and was supported by pre-Seed financing from BioGeneration Ventures. Artica is dedicated to developing novel small molecule medicines for inflammatory and autoimmune indicatons. Artca is at the forefront of covalent binding technology as well as in label-free cellular-based screening approaches. The unique combinaton of these capabilities allows rapid progression of the best drug candidates that have unprecedented and superior characteristics, creating novel and highly selective therapies for patients with unmet medical need.
Location: Netherlands, South Holland, Leiden
Employees: 1-10
Total raised: $12.9M
Founded date: 2020
Investors 1
| Date | Name | Website |
| 07.12.2023 | Seroba Lif... | seroba-lif... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.11.2023 | Seed | $12.9M | - |
Mentions in press and media 3
| Date | Title | Description |
| 10.11.2023 | Artica Therapeutics Closes €12M Seed Investment to Develop Covalent Therapeutics for Autoimmune and Inflammatory Disorders. | Leiden, The Netherlands. 2 November, 2023. Artica Therapeutics B.V. (Artica), a biotechnology company unlocking the power of medicines with insurmountable binding characteristics, today announced it has raised €12 million in Seed financing.... |
| 03.11.2023 | Dutch-based Artica Therapeutics bags €12M to help patients suffering from autoimmune and inflammatory disorders | Read this article in: Leiden-based Artica Therapeutics, a biotechnology company, announced on Thursday, November 2 that it has secured €12M in a seed round of funding. The funding round was co-led by Thuja Capital and Seroba, with participa... |
| - | Artica Therapeutics | “Artica Therapeutics” |